Guson Kang1, Richard Ha2, Dipanjan Banerjee3. 1. Department of Medicine, the Stanford University School of Medicine. 2. Division of Adult Cardiac Surgery, Department of Cardiothoracic Surgery. 3. Department of Medicine, the Stanford University School of Medicine; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: dipanjan@stanford.edu.
Abstract
BACKGROUND: Right ventricular failure (RVF) is a major cause of morbidity and mortality after left ventricular assist device (LVAD) implantation. The pulmonary artery pulsatility index (PAPi) is a novel hemodynamic index that predicts RVF in the setting of myocardial infarction, although it has not been shown to predict RVF after LVAD implantation. METHODS: We performed a retrospective, single-center analysis to examine the utility of the PAPi in predicting RVF and RV assist device (RVAD) implantation in 85 continuous-flow LVAD recipients. We performed a multivariate logistic regression analysis incorporating previously identified predictors of RVF after LVAD placement, including clinical and echocardiographic variables, to determine the independent effect of PAPi in predicting RVF or RVAD after LVAD placement. RESULTS: In this cohort, the mean PAPi was 3.4 with a standard deviation of 2.9. RVF occurred in 33% of patients, and 11% required a RVAD. Multivariate analysis, adjusting for age, blood urea nitrogen (BUN), and Interagency Registry for Mechanically Assisted Circulatory Support profile, revealed that higher PAPi was independently associated with a reduced risk of RVAD placement (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.07-0.89). This relationship did not change significantly when echocardiographic measures were added to the analysis. Stratifying the analysis by the presence of inotropes during catheterization revealed that PAPi was more predictive of RVAD requirement when measured on inotropes (OR, 0.21; 95% CI, 0.02-0.97) than without (OR, 0.49; 95% CI, 0.01-1.94). Furthermore, time from catheterization to LVAD did not significantly affect the predictive value of the PAPi (maximum time, 6 months). Receiver operating characteristic curve analysis revealed that optimal sensitivity and specificity were achieved using a PAPi threshold of 2.0. CONCLUSIONS: In LVAD recipients, the PAPi is an independent predictor of RVF and the need for RVAD support after LVAD implantation. This index appears more predictive in patients receiving inotropes and was not affected by time from catheterization to LVAD in our cohort.
BACKGROUND: Right ventricular failure (RVF) is a major cause of morbidity and mortality after left ventricular assist device (LVAD) implantation. The pulmonary artery pulsatility index (PAPi) is a novel hemodynamic index that predicts RVF in the setting of myocardial infarction, although it has not been shown to predict RVF after LVAD implantation. METHODS: We performed a retrospective, single-center analysis to examine the utility of the PAPi in predicting RVF and RV assist device (RVAD) implantation in 85 continuous-flow LVAD recipients. We performed a multivariate logistic regression analysis incorporating previously identified predictors of RVF after LVAD placement, including clinical and echocardiographic variables, to determine the independent effect of PAPi in predicting RVF or RVAD after LVAD placement. RESULTS: In this cohort, the mean PAPi was 3.4 with a standard deviation of 2.9. RVF occurred in 33% of patients, and 11% required a RVAD. Multivariate analysis, adjusting for age, blood ureanitrogen (BUN), and Interagency Registry for Mechanically Assisted Circulatory Support profile, revealed that higher PAPi was independently associated with a reduced risk of RVAD placement (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.07-0.89). This relationship did not change significantly when echocardiographic measures were added to the analysis. Stratifying the analysis by the presence of inotropes during catheterization revealed that PAPi was more predictive of RVAD requirement when measured on inotropes (OR, 0.21; 95% CI, 0.02-0.97) than without (OR, 0.49; 95% CI, 0.01-1.94). Furthermore, time from catheterization to LVAD did not significantly affect the predictive value of the PAPi (maximum time, 6 months). Receiver operating characteristic curve analysis revealed that optimal sensitivity and specificity were achieved using a PAPi threshold of 2.0. CONCLUSIONS: In LVAD recipients, the PAPi is an independent predictor of RVF and the need for RVAD support after LVAD implantation. This index appears more predictive in patients receiving inotropes and was not affected by time from catheterization to LVAD in our cohort.
Authors: Justin A Fried; Abhinav Nair; Koji Takeda; Kevin Clerkin; Veli K Topkara; Amirali Masoumi; Melana Yuzefpolskaya; Hiroo Takayama; Yoshifumi Naka; Daniel Burkhoff; Ajay Kirtane; Dimitrios Karmpaliotis; Jeffrey Moses; Paolo C Colombo; A Reshad Garan Journal: J Heart Lung Transplant Date: 2018-03-20 Impact factor: 10.247
Authors: David S Raymer; Jonathan D Moreno; Marc A Sintek; Michael E Nassif; Christopher T Sparrow; Luigi Adamo; Eric L Novak; Shane J LaRue; Justin M Vader Journal: ASAIO J Date: 2019 Mar/Apr Impact factor: 2.872
Authors: Michael S Kiernan; E Wilson Grandin; Marshall Brinkley; Navin K Kapur; Duc Thinh Pham; Robin Ruthazer; J Eduardo Rame; Pavan Atluri; Edo Y Birati; Guilherme H Oliveira; Francis D Pagani; James K Kirklin; David Naftel; Robert L Kormos; Jeffrey J Teuteberg; David DeNofrio Journal: Circ Heart Fail Date: 2017-10 Impact factor: 8.790
Authors: Sula Mazimba; Timothy S Welch; Hunter Mwansa; Khadijah K Breathett; Jamie L W Kennedy; Andrew D Mihalek; William C Harding; Manu M Mysore; David X Zhuo; Kenneth C Bilchick Journal: Heart Lung Circ Date: 2018-04-17 Impact factor: 2.975